Rykindo Patent Expiration

RYKINDO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9446135 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US11110094 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US10406161 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US10098882 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)

US9532991 SHANDONG LUYE Risperidone sustained release microsphere composition
Apr, 2032

(7 years from now)



Rykindo is a drug owned by Shandong Luye Pharmaceutical Co Ltd. It is used for treating schizophrenia in adults. Rykindo uses Risperidone as an active ingredient. Rykindo was launched by Shandong Luye in 2023. It is is available in for suspension, extended release form for intramuscular use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 10, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RISPERIDONE ingredient

Market Authorisation Date: 13 January, 2023

Treatment: Treatment of schizophrenia in adults

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

RYKINDO family patents

Family Patents